With this new fund raising, Oncomfort will expand possibilities of “Digital Sedation” product. The company wants also to be more present on the US market. You can note that one of the investors is the swiss Debiopharm, a biopharmaceutical group of companies active in drug development.
Oncomfort plans to use the €10 million of this Series A funding round to further develop its solution and accelerate its international expansion across the European and American markets. The investment round was realized with two leading institutional investors, the Swiss Debiopharm, and the French Crédit Mutuel Innovation (CMI), and also includes continuing support from Wallonia Innovation and Growth (W.IN.G), plus existing investors.
